{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:37Z","timestamp":1779084457584,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of complete revascularization (CR) versus incomplete revascularization (ICR) on the composite outcome of first hospitalization for heart failure (HF) or cardiovascular death in patients with acute coronary syndrome (ACS) and a left ventricular ejection fraction (LVEF)\u2009\u2265\u200940%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 1,834 patients with ACS, multivessel disease, and an LVEF \u2265 40% (767 CR and 1,067 ICR). CR was defined as percutaneous coronary intervention (PCI) of all suitable non-culprit lesions during index hospitalization or within 45 days postdischarge. The primary endpoint was the first occurrence of hospitalization for HF or cardiovascular death. At discharge, almost all patients received dual antiplatelet therapy and guideline-directed medical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      During the follow-up period, 35 of the 767 patients (4.6%) in the CR group and 83 of the 1,067 (7.8%) patients in the ICR group reached the primary endpoint (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). After adjusting for covariates, CR was associated with a lower risk of the primary endpoint in the population with an LVEF &amp;lt;50% [hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.22\u20130.96]. This benefit was confined to patients with non-ST-segment elevation ACS (NSTE\u2013ACS) (HR 0.41; 95% CI 0.20\u20130.83) but was not observed in the ST-segment elevation myocardial infarction (STEMI) subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CR is associated with a significantly reduced risk of HF hospitalization or cardiovascular death in patients with an LVEF of 40%\u201350%. This benefit attenuated as the LVEF increased, highlighting a potential LVEF-dependent efficacy. Although these results are promising, the observational nature of this study and the potential for residual confounding necessitate cautious interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1830626","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:41:32Z","timestamp":1779082892000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete revascularization and heart failure risk in acute coronary syndrome across the ejection fraction spectrum: focus on LVEF-dependent effects"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaozhi","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities","place":["Baise, Guangxi, China"]},{"name":"Department of Cardiology, Laboratory of the Atherosclerosis and Ischemic Cardiovascular Diseases","place":["Baise, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaan","family":"Nong","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine, Guangxi Zhuang Autonomous Region Brain Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities","place":["Baise, Guangxi, China"]},{"name":"Department of Cardiology, Laboratory of the Atherosclerosis and Ischemic Cardiovascular Diseases","place":["Baise, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyuan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities","place":["Baise, Guangxi, China"]},{"name":"Department of Cardiology, Laboratory of the Atherosclerosis and Ischemic Cardiovascular Diseases","place":["Baise, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingshou","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities","place":["Baise, Guangxi, China"]},{"name":"Department of Cardiology, Laboratory of the Atherosclerosis and Ischemic Cardiovascular Diseases","place":["Baise, Guangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e028475","DOI":"10.1161\/JAHA.122.028475","article-title":"Impact of complete revascularization on development of heart failure in patients with acute coronary syndrome and multivessel disease: a subanalysis of the CORALYS registry","volume":"12","author":"Bruno","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10557-025-07720-2","article-title":"Effects of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers on prognosis in acute coronary syndrome patients with preserved ejection fraction undergoing regular dialysis","volume":"40","author":"Li","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jchf.2024.04.027","article-title":"Low natriuretic peptide levels and outcomes in patients with heart failure and preserved ejection fraction","volume":"12","author":"Kondo","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/CIRCULATIONAHA.122.063642","article-title":"Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification?","volume":"148","author":"Kondo","year":"2023","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ehjcvp\/pvad069","article-title":"Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry","volume":"10","author":"Spirito","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ahj.2019.06.006","article-title":"Design and rationale of the COMPLETE trial: a randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction","volume":"215","author":"Mehta","year":"2019","journal-title":"Am Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ahj.2020.08.007","article-title":"Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: rationale and design of the FIRE trial","volume":"229","author":"Biscaglia","year":"2020","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2300468","article-title":"Complete or culprit-only PCI in older patients with myocardial infarction","volume":"389","author":"Biscaglia","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00392-025-02719-z","article-title":"Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies","volume":"115","author":"Parhofer","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards)","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jtcvs.2021.08.040","article-title":"Percutaneous coronary intervention versus coronary artery surgery for left main disease according to lesion site: a meta-analysis","volume":"166","author":"De Filippo","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjcard.2021.07.005","article-title":"Benefit of extended dual antiplatelet therapy duration in acute coronary syndrome patients treated with drug eluting stents for coronary bifurcation lesions (from the BIFURCAT registry)","volume":"156","author":"De Filippo","year":"2021","journal-title":"Am J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijcard.2022.10.146","article-title":"Incidence and predictors of heart failure after acute coronary syndrome: the CORALYS registry","volume":"370","author":"De Filippo","year":"2023","journal-title":"Int J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/0735-1097(95)00089-m","article-title":"Residual exertional ischemia and unfavorable left ventricular remodeling in patients with systolic dysfunction after anterior myocardial infarction","volume":"25","author":"Giannuzzi","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1153625","DOI":"10.3389\/fcvm.2023.1153625","article-title":"A plasma proteomic approach in patients with heart failure after acute myocardial infarction: insights into the pathogenesis and progression of the disease","volume":"10","author":"Liu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e013737","DOI":"10.1161\/CIRCINTERVENTIONS.123.013737","article-title":"Culprit-only revascularization, single-setting complete revascularization, and staged complete revascularization in acute myocardial infarction: insights from a mixed treatment comparison meta-analysis of randomized trials","volume":"17","author":"Maqsood","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","article-title":"One-year outcomes after PCI strategies in cardiogenic shock","volume":"379","author":"Thiele","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacc.2017.12.028","article-title":"Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock","volume":"71","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jcin.2021.02.021","article-title":"Multivessel versus culprit-vessel percutaneous coronary intervention in patients with non-ST-segment elevation myocardial infarction and cardiogenic shock","volume":"14","author":"Omer","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10557-024-07636-3","article-title":"Ticagrelor versus clopidogrel in patients with left main coronary artery stenting","volume":"39","author":"Yan","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.4103\/0366-6999.239306","article-title":"Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"131","author":"Wang","year":"2018","journal-title":"Chin Med J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1830626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:41:35Z","timestamp":1779082895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1830626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2026.1830626"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1830626","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1830626"}}